Overall, while it remains to be determined whether mutated BRAF represents an actionable target for HSP90 inhibitor therapy in CRC, our findings suggest that the full potential of ganetespib is likely to be realized as part of novel combinatorial approaches in this disease. This evidence concerns the gene BRAF and colorectal carcinoma.